Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14531834 | 1.00 | CHRM2 (0.37) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL18664135 | 1.00 | CHRM2 (0.37) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL16994171 | 1.00 | CHRM2 (0.37) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL21598839 | 0.82 | CHRM2 (0.33) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Hydrochloric Acid SCHEMBL27785352 | 0.80 | CHRM2 (0.32) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL28327117 | 0.79 | — | — | |
| SCHEMBL683685 | 0.78 | CHRM2 (0.36) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL21111358 | 0.78 | CHRM2 (0.36) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL30302218 | 0.77 | — | — | |
| SCHEMBL5861606 | 0.76 | CYP2D6 (0.48) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3501546-A2 | CYSTEINE DRUG CONJUGATES AND USE OF SAME | Seattle Genetics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2017046606-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-8992932-B2 | Binder-drug conjugates (ADCs) and use thereof | SEATTLE GENETICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150030618-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | SEATTLE GENETICS, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | MDN1, EPCAM, VCAM1 | CHRM2 2041/4885CHRM4 2403/4885CHRM1 1943/4885 |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | CHRM2 2388/4885CHRM4 1224/4885CHRM1 1758/4885 |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | CHRM2 2388/4885CHRM4 1224/4885CHRM1 1758/4885 |
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | FGFR2, FGFR1, FGFR3 | CHRM2 3835/4885CHRM4 4255/4885CHRM1 4019/4885 |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | DDR1, IGFBP6, KDR | CHRM2 3130/4885CHRM4 3875/4885CHRM1 3426/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | CHRM2 3130/4885CHRM4 3875/4885CHRM1 3426/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | CHRM2 2388/4885CHRM4 1224/4885CHRM1 1758/4885 |
| US-20150030618-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | CHRM2 2446/4885CHRM4 1289/4885CHRM1 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.